JPMorgan Chase & Co. lowered shares of GALAPAGOS NV/S (NASDAQ:GLPG) from an overweight rating to a neutral rating in a research note issued to investors on Sunday morning, BenzingaRatingsTable reports. They currently have $205.00 price objective on the biotechnology company’s stock.
Other analysts have also issued research reports about the company. Morgan Stanley lowered GALAPAGOS NV/S from an overweight rating to an equal rating and boosted their price target for the company from $193.00 to $215.00 in a report on Tuesday, December 17th. UBS Group lowered GALAPAGOS NV/S from a buy rating to a neutral rating in a report on Friday, December 20th. Zacks Investment Research lowered GALAPAGOS NV/S from a buy rating to a hold rating in a report on Thursday, October 31st. Royal Bank of Canada boosted their price target on GALAPAGOS NV/S from $152.00 to $158.00 and gave the company a sector perform rating in a report on Friday, November 15th. Finally, Bank of America began coverage on GALAPAGOS NV/S in a report on Monday, December 2nd. They issued a neutral rating and a $199.00 price target for the company. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $182.00.
Shares of NASDAQ:GLPG opened at $206.72 on Friday. GALAPAGOS NV/S has a 1 year low of $94.75 and a 1 year high of $217.29. The business has a 50 day simple moving average of $204.66 and a two-hundred day simple moving average of $173.59. The firm has a market capitalization of $11.36 billion, a PE ratio of -313.21 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.95 and a quick ratio of 8.95.
A number of large investors have recently modified their holdings of GLPG. Tower Research Capital LLC TRC increased its position in shares of GALAPAGOS NV/S by 170.7% during the second quarter. Tower Research Capital LLC TRC now owns 249 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 157 shares in the last quarter. Royal Bank of Canada increased its position in shares of GALAPAGOS NV/S by 206.1% during the second quarter. Royal Bank of Canada now owns 251 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 169 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. acquired a new position in shares of GALAPAGOS NV/S during the second quarter worth $59,000. Quantamental Technologies LLC acquired a new position in shares of GALAPAGOS NV/S during the second quarter worth $74,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of GALAPAGOS NV/S during the third quarter worth $109,000. 15.28% of the stock is owned by institutional investors.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.